CTI BioPharma Corp. (CTIC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.40+0.05 (+14.86%)
At close: 4:00 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close0.35
Bid0.38 x 10000
Ask0.44 x 25900
Day's Range0.38 - 0.48
52wk Range0.25 - 1.75
1y Target EstN/A
Market Cap113.69M
P/E Ratio (ttm)-1.24
Avg Vol (3m)1,321,500
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Benzinga3 hours ago

    CTI BioPharma Meets One Of Two Endpoints In Phase 3 Trial

    CTI BioPharma Corp. (NASDAQ: CTIC ) shares are trading higher on Monday after the company announced its preliminary results of PERSIST-2 that met one of the co-primary endpoints in phase three study. Earlier, ...

  • PR Newswire11 hours ago

    CTI BioPharma Announces Top-Line Results From PERSIST-2 Phase 3 Trial Of Pacritinib For High-Risk Patients With Advanced Myelofibrosis

    SEATTLE, Aug. 29, 2016 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced top-line results from PERSIST-2, a randomized, controlled Phase 3 clinical trial comparing pacritinib, an investigational oral multikinase inhibitor, with physician-specified best available therapy (BAT), including ruxolitinib, for the treatment of patients with myelofibrosis whose platelet counts are less than 100,000 per microliter -- a patient population with high-risk advanced disease. Preliminary results demonstrated that the PERSIST-2 trial met one of the co-primary endpoints showing a statistically significant response rate in spleen volume reduction (SVR) in patients with myelofibrosis treated with pacritinib compared to BAT, including the approved JAK2 inhibitor ruxolitinib (p

  • Associated Press25 days ago

    CTI BioPharma reports 2Q loss

    The Seattle-based company said it had a loss of 7 cents per share. Losses, adjusted for stock option expense, came to 6 cents per share. The biotechnology company posted revenue of $7.4 million in the ...